Compare Royal Bank of Canada (RY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Travere Therapeutics Inc. Common Stock — how do they compare? Royal Bank of Canada trades at $193.8 (market cap $268.76B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Royal Bank of Canada is far larger — about 55.1× Travere Therapeutics Inc. Common Stock's market cap, and Royal Bank of Canada pays a 2.61% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 48 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RY | TVTX | |
|---|---|---|
Market Cap | $268.76B | $4.88B |
Volume | 1,509,016 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $217.87 | $67.52 |
52-Week Low | $145.31 | $26.79 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $738.98B | $5.01B |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $193.82, up 0.55% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with net income margin improving to 32.01%. Analyst consensus leans neutral with 43% buy ratings while technical indicators show resistance near $194.
RY presents a mixed outlook with robust profitability and dividend stability offset by stretched valuations and bearish technicals. The bank's 18% ROE and U.S. expansion provide upside potential, though high P/E of 17.5 and negative cash flow trends warrant caution. Near-term performance hinges on Q3 earnings due October 2026.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
